Cancer cells evolve several alterations in their metabolism to survive in unfavorable microen vironments, while retaining their ability to pro liferate (Vander Heiden et al., 2009) . A classical metabolic adaptation of tumor cells is a shift to aerobic glycolysis as a main source of ATP, rather than oxidative phosphorylation (OXPHOS), ir respective of oxygen availability, a phenomenon referred to as the Warburg effect (Warburg, 1956 ). This phenotype may promote a state of apoptosis resistance (Plas and Thompson, 2002; Kroemer and Pouyssegur, 2008) , the generation of biosynthetic precursors for proliferation (Vander Heiden et al., 2009) , and increased in vasive ability (Stern et al., 2002) . The molecular basis of aerobic glycolysis remains elusive and may vary across cancers. Genetic and epigenetic alterations in key enzymes resulting in metabolic modification include primary mutations, altered isoform expression profile, and altered regula tion/function secondary to oncogenic signal ing pathways or the tumor microenvironment (Vander Heiden et al., 2009 ).
An example of alterations in the isoform expression profile of metabolic enzymes is ex emplified by a switch in splice isoforms from the adult pyruvate kinase muscle 1 (PKM1) to the fetal PKM2, which is believed to promote aerobic glycolysis and tumor growth in lung cancer cell lines (Christofk et al., 2008) . Primary mutations in isocitrate dehydrogenase-1 (IDH1), Proliferating embryonic and cancer cells preferentially use aerobic glycolysis to support growth, a metabolic alteration commonly referred to as the "Warburg effect." Here, we show that the glycolytic enzyme hexokinase 2 (HK2) is crucial for the Warburg effect in human glioblastoma multiforme (GBM), the most common malignant brain tumor. In contrast to normal brain and low-grade gliomas, which express predominantly HK1, GBMs show increased HK2 expression. HK2 expression correlates with worse overall survival of GBM patients. Depletion of HK2, but neither HK1 nor pyruvate kinase M2, in GBM cells restored oxidative glucose metabolism and increased sensitivity to cell death inducers such as radiation and temozolomide. Intracranial xenografts of HK2-depleted GBM cells showed decreased proliferation and angiogenesis, but increased invasion, as well as diminished expression of hypoxia inducible factor 1 and vascular endothelial growth factor. In contrast, exogenous HK2 expression in GBM cells led to increased proliferation, therapeutic resistance, and intracranial growth. Growth was dependent on both glucose phosphorylation and mitochondrial translocation mediated by AKT signaling, which is often aberrantly activated in GBMs. Collectively, these findings suggest that therapeutic strategies to modulate the Warburg effect, such as targeting of HK2, may interfere with growth and therapeutic sensitivity of some GBMs.
PKM2, restored normal oxidative glucose metabolism with decreased extracellular lactate and increased expression of OXPHOS proteins and O 2 consumption. HK2 depletion re duced in vitro and in vivo growth of GBMs, with increased sensitivity to apoptosis induced by hypoxia, radiation, or che motherapy. Furthermore, the growthpromoting effects of HK2 require both glucose phosphorylation and mitochondrial localization, mediated by activation of the PI3K-AKT signaling pathway, which is known to be aberrant in GBMs (Gottlob et al., 2001; Pastorino et al., 2002; Majewski et al., 2004) .
RESULTS

Human GBMs express HK2, correlating with poor overall survival
To establish whether HK2 is expressed in human GBM sam ples, Western blot for HK2 expression was performed on 3 normal human brains, 5 LGA and 12 GBM specimens ( Fig. 1 A) . At least eight of the GBM specimens expressed HK2, whereas normal human brains and LGAs only expressed HK1. Immuno histochemical staining of HK2 on a survival tissue micro array of 56 primary and secondary GBMs demonstrated that 35 (62.5%) expressed HK2, whereas 21 (37.5%) did not (Cohen's  = 0.81; P < 0.005; Guo et al., 2009 ). HK2 expression cor related with a poorer prognosis, even when controlling for age (Fig. 1 B ; Cox proportional hazard, P < 0.006).
To determine whether HK2 transcript varies with GBM subtype, we data mined the recently published significance analysis of microarrays from The Cancer Genome Atlas's pair wise analysis comparing transcript expression across different GBM subtypes (Verhaak et al., 2010) . HK2 expression was lowest in the neural subtype and strongest in the mesenchy mal subtype, where PTEN and NF1 mutations predominate. HK2 transcript was intermediate in expression in the proneu ral subtype, in which IDH1 mutations predominantly occur (Table S1 ). None of the 12 GBM specimens were found to express mutant IDH1 (Fig. S1 A) . Overall, there does not ap pear to be a relationship between HK2 and mutant IDH1 in GBM tissues.
HK2 is strongly expressed in the perinecrotic region of human GBMs Increased apoptosis would be predicted for the pseudopali sading perinecrotic hypoxic cells around central regions of GBMs. However, TUNEL staining on 25 paired center and periphery GBM samples demonstrated almost equivalent and low apoptotic indices (<1%; Fig. S1 B) . Quantitative RTPCR (qRTPCR) on microdissected cells from 12 paired GBM center and periphery cryosections demonstrated higher HK2 expression in the central pseudopalisading versus invading GBM cells of the periphery (Fig. 1 C ; P = 0.04). HK1 expres sion was not differentially expressed (P = 0.20). Immunohis tochemical staining was performed on the 25 paired GBM specimens, 6 LGAs, and 3 normal brain samples. Normal brain white matter did not express HK2, LGAs expressed low to none, and 20/25 GBMs expressed high levels of HK2, especially in the pseudopalisading cells (Fig. S1 C) . a metabolic enzyme, was recently identified in glioblastoma multiforme (GBM; Parsons et al., 2008; Yan et al., 2009) , which is the most common and lethal of all primary human central nervous system tumors (Mellinghoff et al., 2005; Stupp et al., 2005) . Highthroughput genomic screening of GBMs identified a point mutation (predominantly R132H) in the IDH1 gene in 12% of all GBMs (Parsons et al., 2008) and 80% of lowgrade astrocytomas (LGA) or secondary GBMs that developed from their malignant progression (Watanabe et al., 2009; Yan et al., 2009) . Mutation in IDH1 results in neomorphic activity, producing a different metabolite, 2hydroxyglutaric acid, whereas wildtype IDH1 normally con verts isocitrate to ketoglutarate coupled with NADP + / NADPH. The impact of this mutation and of the accumulation of the metabolite 2hydroxyglutarate on GBM metabolism and glucose utilization and subsequent growth remains unclear Zhao et al., 2009 ). However, >90% of GBMs are primary GBMs and the molecular basis of the Warburg effect in this subset of GBMs is under active investigation.
As denoted by "multiforme," GBMs are pathologically heterogeneous with "central" regions of necrosis surrounded by florid cellular (pseudopalisading cells) and hypervascular ized regions under moderate levels of hypoxic stress (pO2, 2.5-5%; Evans et al., 2004) . GBMs also have "peripheral" re gions, which consist of invading tumor cells into normal brain. GBM cells are resistant to standard apoptoticinducing therapies, including radiation and chemotherapy, and are highly invasive (Brat et al., 2004) . GBMs demonstrate an ap proximately threefold increase in glycolysis relative to normal brain (Oudard et al., 1996) , with variations across different GBM cell lines (Gorin et al., 2004; Griguer et al., 2005) .
In this study, we provide evidence demonstrating that the glycolytic enzyme hexokinase 2 (HK2) is aberrantly expressed in GBMs and is an important mediator of aerobic glycolysis in GBMs, providing a proliferative and cell survival advantage. HK2 is expressed at basal levels in skeletal and adipose tissue, but negligently in normal brain, which predominantly ex presses HK1. Several transcription and growth factors known to promote GBM growth, including insulin growth factor, myc, glucagon, and cAMP, among others, also modulate HK2 expression and activity with reduced or no effect on HK1 expression (Mathupala et al., 1995; Mathupala et al., 2001) . Hypoxia inducible factor 1 (HIF1) upregulates many enzymes of the glycolytic pathway, including HK2, by bind ing to hypoxiaresponsive elements (HREs) in the HK2 pro moter (Mathupala et al., 2001 ). In addition, GBMs are known to have aberrant activation of growth factor receptors and/or loss of PTEN activity (Mellinghoff et al., 2005) with subse quent activation of the PI3K-AKT pathway. Upon AKT activa tion, HK2 may undergo translocation to the outer mitochondrial membrane and interact with the permeability transition pore, which includes the voltagedependent anion channel (VDAC) and Bax to promote cell survival (Gottlob et al., 2001; Pastorino et al., 2002; Majewski et al., 2004) .
Results from this study demonstrate that inhibition of HK2, but not of the glycolytic enzymes HK1 or downstream was significantly decreased (Fig. 2 B ; P < 0.05), whereas the change in caspase 3 and 7 activity was insignifi cant in U87 cells (Fig. 2 C) . How ever, under hypoxic conditions, there was a significant increase in caspase 3 and 7 activity (Fig. 2 C ; P < 0.05) and Annexin V labeling on flow cyto metry in U87 cells (Fig. S2 D) , indicating increased apop tosis as a result of transient HK2 knockdown. In addition, caspase 3 and 7 activity assay demonstrated that U87 and U373 cells depleted of HK2 were significantly more sensi tive to apoptosis induced by radiation (Fig. 2 C ; P < 0.05). Of clinical relevance, HK2 knockdown decreased the via bility of GBM cells, particularly U87 cells, exposed to te mozolomide (TMZ), the only current chemotherapeutic drug with demonstrated clinical efficacy in GBMs (Fig. 2 D ; Stupp et al., 2005) .
To validate the importance of HK2 in proliferation and resistance to apoptosis in GBM cells, we depleted HK2 for 7 d in GBM explants established by D. James (GBM6 and GBM8; Fig. S3 , A and B; Sarkaria et al., 2006) , which have been cultured transiently and thus are not subject to genetic pressures arising as a result of continuous passages under high glucose and growth factor conditions. Depletion of HK2 in GBM6 and GBM8 cells after 7 d resulted in reduction in proliferation (fold difference in BrdU) to 60% of control cells. Depletion of HK2 synergized with radiation (P < 0.05) or TMZ therapy (P < 0.01) in reducing proliferation of GBM6 cells, but not GBM8 cells (Fig. S3 C) . Furthermore, GBM6 and GBM8 cells depleted of HK2 did not demon strate enhanced apoptosis, measured by caspase 3 and 7 activ ity, when treated with TMZ. However, the combination of radiation and HK2 inhibition resulted in elevated caspase 3 and 7 activity in GBM6 and GBM8 cells (Fig. S3 D; P < 0.05). To determine whether there exists a differential sensi tivity to HK2 depletion based on the level of HK2 over expression in GBM cells, we transfected U87 cells (high expression) and U138 cells (lower expression) with 25 or 50 nM Our laboratory has previously established a GFAP: V12 HaRas genetically engineered mouse model in which mice are born normal but develop LGAs and highgrade astro cytomas (HGA), which when characterized are similar to their human counterparts (Ding et al., 2001) . Immunohisto chemical staining of HK2 on three LGAs and three HGAs from GFAP: V12 HaRas mice demonstrate expression of HK2 in 0/3 LGA and 2/3 HGA (Fig. S1 D) .
Knockdown of HK2 decreases GBM cell proliferation and sensitizes them to therapeutic and microenvironmental inducers of apoptosis The stronger expression of HK2 within the harsher central microenvironments suggests that it may be providing a survival advantage to GBM cells. To answer this, control scramble small interfering RNA (siRNA) and HK2siRNA were transfected into U87 and U373 human GBM cell lines to determine whether HK2 confers a proliferative and/or cell survival advantage. HK2 was almost completely abolished 72 h after transfection (Fig. 2 A) , without any al teration in HK1 or PKM2 levels (Fig. S2 C) . Cell viability, measured by sulphorhodamine B (SRB) assay and trypan blue exclusion, was lower in U87 and U373 HK2siRNA transfected cells (P < 0.005; Fig. S2 A ) . The decrease in cell viability was further enhanced by 2% hypoxia (P < 0.005; Fig. S2 B) , which did not alter the suppression of HK2 by HK2siRNA (Fig. S2 C) . BrdU incorporation and caspase 3 and 7 activity assays were undertaken to determine whether the decreased cell viability was caused by reduced prolifer ation, increased cell death, or both. In normoxic conditions, at 120 h after transfection of HK2siRNA, proliferation potentially mediate the effect HK2 depletion on GBM cell proliferation and death.
Knockdown of HK2 sensitizes GBM cells to apoptosis by increasing mitochondrial membrane permeability To elucidate the mechanisms involved in HK2mediated metabolic remodel ing, mitochondrial function, and resis tance to apoptosis, HK2 was stably depleted using two different short hairpin RNAs (shRNAs; HK2shRNA1 and HK2shRNA2) in U87 GBM cells (PTEN null, over expressed AKT, and p53 wt) that express high levels of HK2 (Fig. 3 A) . Transmission electron microscopy and immunofluo rescence of live cells stained with a MitoTracker dye demon strated no difference in morphology or number of mitochondria between scramble (scr) shRNA and U87HK2shRNA1 and U87HK2shRNA2 ( Fig. S4, A and B) . FACS analysis of cells stained with nonyl acridine orange demonstrated that mitochondrial mass also did not differ significantly between U87scr (1,906 ± 337), U87HK2shRNA1 (1,553 ± 307), and U87HK2shRNA2 (1,675 ± 289) cells.
HK2 has previously been reported to translocate to the mitochondria and interact with members of the permeabil ity transition pore at the outer mitochondrial membrane (Pastorino et al., 2002; Majewski et al., 2004) . This translocation of HK2siRNA for 7 d. U87 cells were found to have greater reduction in cell viability compared with U138 cells at 25 and 50 nM of HK2siRNA (Fig. S3 E) . Similarly, U87 cells that expressed wildtype PTEN, an important regulator of growth factor signaling in GBMs, demonstrated reduced responsive ness to HK2 depletion compared with U87 cells in which PTEN is deleted (Fig. S3 E) . Overall, these results support an important role of HK2 depletion in GBM cells that express varying levels of HK2 and the potential synergistic effects with radiation or TMZ, by impacting either proliferation or apoptosis, depending on the genetic background of GBM cells. GBM6 and GBM8 cells differ in respect to several im portant regulators of metabolism and mediators of response to TMZ, including status of the DNA repair enzyme MGMT and the expression of PTEN and p53 (Fig. S3 A) , which may , an oral alkylating agent used in the treatment of GBMs. Proliferation, cell viability, and caspase assays were performed in triplicate and represented as mean ± SEM of three independent experiment. *, P < 0.05.
an effect that was more pronounced under hypoxic condi tions (Fig. 3 C) .
Stable loss of HK2 reverts GBM cells to normal oxidative glucose metabolism
To determine if decreasing HK2 reverts aerobic glycolysis to OXPHOSdependent glucose metabolism, proteins, tran scription factors, O 2 consumption, and byproducts of OXPHOS metabolism were evaluated in U87HK2shRNA1 and U87HK2shRNA2 GBM cells. OXPHOSassociated pro teins involved in the electron transport chain (part of com plexes I/II/III/IV/V) were increased in both HK2depleted U87 GBM cell lines, compared with those transfected with control scr shRNA ( Fig. 3 A) . and interaction regulates the release of cytochrome c, a critical step in the intrinsic apoptotic pathway (Majewski et al., 2004) . To determine the effect of stable loss of HK2 on mitochondrial membrane potential under hypoxic conditions, live U87 cells were stained with the ratiomet ric indicator JC1 and analyzed by confocal microscopy. Greater depolarization in U87HK2shRNA1 cells (Fig. 3 B) was observed compared with U87scr, as reflected by signifi cant reduction in the red:green fluorescence ratio (P = 0.014). Furthermore, cytosolic cytochrome c level mea sured on ELISA were greater in both U87HK2shRNA1 and U87HK2shRNA2 cells, compared with U87scr (P < 0.05), was measured using Clark-type oxygen electrode monitoring dissolved oxygen concentration in a sealed chamber over time.
(F) Extracellular lactate in indicated U87 cells was measured by a NADH-coupled enzyme reaction with absorbance measured at 490 nm, and normalized to cell number. qRT-PCR, O 2 consumption, and lactate measurements were performed in triplicates and graphs show mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01.
phosphorylation and mitochondrial binding) were transfected into U343 cells. Overexpression of HK2GFP in U343 cells provided protection against radiationinduced apoptosis, re flected by a smaller increase in cytosolic cytochrome c and caspase 3 and 7 activity compared with cells expressing mu tant or truncated HK2 (Fig. 4, C and D) . Similarly, prolifera tion of U343 HK2GFP cells was increased compared with control (GFP) and U343 HK1GFP-expressing cells after 3 d of +EGF (Fig. 4 E) . Both U343 T2GFP and M2GFP had decreased proliferation compared with HK2GFP, suggesting that both glucose phosphorylation and the Nterminal mito chondrial binding domain contribute to HK2's proliferative effects, although glucose phosphorylation does so to a greater extent (Fig. 4 E) .
Differential role of HK2 versus HK1 or PKM2 on GBM metabolism and proliferation To determine whether HK1, which like HK2 converts glucose to glucose6phosphate (Wilson, 2003) , or PKM2, another downstream ratelimiting glycolytic enzyme, also regulate aerobic glycolysis in GBMs, shRNAs toward HK1 and PKM2 were generated in U87 human GBM lines (Fig. 5 A) . Total HK activity level was reduced compared to control U87 cells expressing scr shRNA in cells depleted of HK2 and HK1 (Fig. 5 B) . Similar to loss of HK2, loss of HK1 and PKM2 did not alter mitochondrial number or morphology (Fig. S4 B) . However, unlike HK2, depleted HK1 or PKM2 did not reduce extracellular lactate (Fig. 5 C) or increase O 2 consumption (Fig. 5 D) . Expression of pyruvate dehydroge nase E1  (PDHE1a), an enzyme that plays a key role in the function of the PDH complex, which catalyzes the conver sion of pyruvate to acetylcoA in the mitochondria to un dergo OXPHOS, was elevated with loss of HK2 but not HK1 (Fig. 5 A) . Furthermore, overexpression of HK1GFP in U87 cells depleted of HK2 (Fig. 5 A) did not rescue extra cellular lactate (Fig. 5 C) or inhibit OXPHOS restoration seen with HK2 knockdown (Fig. 5 D) . Overexpression stud ies in U343 cells, which do not express HK2 and minimally express HK1, were also in support of HK2 and not HK1 being the major regulator of aerobic glycolysis in GBMs. In addition to enhanced proliferation, HK2GFP overexpres sion increased extracellular lactate levels by 11% by day 3 compared with control cells (normalized to cell number; Fig. 4 F) , which was not observed in HK1GFP overexpres sion. This was irrespective of total HK activity, which was similar between U343transfected HK2GFP and HK1GFP cells (Fig. S5 C) .
To verify that the decrease in lactate production with de pletion of HK2 is not solely caused by reduced glucose up take, cells were stained with the fluorescent dglucose analogue 2[N(7nitrobenz2oxa1,3diazol4yl)amino]2deoxy dglucose. Interestingly, GBM cells depleted of HK2 showed a significant compensatory increase in glucose uptake, as did U87HK1shRNA to a lesser extent, whereas cells depleted of PKM2 had reduced glucose uptake compared with U87 scr shRNA (Fig. 5 E) . Enhanced glucose uptake was associated Fig. 3 D) . Evidence of a switch to OXPHOSbased metabolism was a greater than twofold increase in O 2 consumption (Fig. 3 E) and reduction of extracellular lactate (Fig. 3 F) in cells lacking HK2 compared with scr shRNA.
Translocation of HK2, and not HK1, to the outer mitochondrial membrane after growth factor stimulation increases proliferation and generation of lactate Previous studies have demonstrated that growth factor stimu lation, resulting in activation of the PI3K-AKT pathway, promotes translocation of HK2 to the outer mitochondrial membrane, resulting in increased protein stability (Bustamante and Pedersen, 1977; Gottlob et al., 2001 ). To test this in GBM cells, U87 cells were treated with the protein synthesis inhibi tor cycloheximide (CHX) with or without EGF stimulation. Without EGF, more than half of HK2 protein was degraded by 12 h of CHX treatment, whereas HK2 protein levels were main tained for up to 20 h when incubated with EGF (Fig. S5 D) .
To evaluate HK2 and HK1 translocation to the mito chondria, U343 GBM cells (HK2 -ve and HK1 +ve; no tumor formation in mice) and U87 GBM cells (+HK2 and +HK1; grow in vivo) were transfected to express HK1GFP or HK2GFP with or without EGF stimulation. U343 HK2 GFP (green) after +EGF showed greater colocalization to mitochondria (blue; white, R = 80 ± 8.9%) compared to EGF conditions (R = 52 ± 12%; Fig. 4 A) . Treatment of U343 cells with AKT inhibitor VIII (2 M) for 6 h under growth factor conditions showed reduced colocalization of HK2 with mitochondria by immunofluorescence (R = 53 ± 6%) and mitochondrial fractionation (Fig. 4, A and B) . In con trast, HK1GFP was found predominantly at mitochondria, irrespective of EGF stimulation (EGF, R = 85 ± 7%; +EGF, R = 83 ± 8%). In U87 cells, a greater proportion of HK2 GFP localized to the mitochondria under EGF conditions (R = 74 ± 14%; +EGF = 81 ± 12%; Fig. S5 A) compared with U343 cells. This is likely a reflection of higher basal pAKT levels in U87 cells, which can be induced with EGF stimulation in U343 cells (Fig. S5 B) . In support, inhibition of PI3K-AKT activation with AG1478 (2 M EGFR inhibitor) in U87 cells decreased HK2 localization to the mitochondria (R = 45 ± 9%; Fig. S5 A) , as did treatment of U87 cells with AKT inhibitor VIII (R = 59 ± 10%). U87 cells in which PTEN has been reintroduced also show reduced mitochon drial localization of HK2 (R = 58 ± 6%; Fig. S5 A) . Similar to U343 cells, HK1GFP localization was predominantly mito chondrial and not altered by EGF (EGF, R = 83 ± 11%; +EGF, R = 84 ± 12%).
We next determined the importance of the catalytic func tion and mitochondrial translocation of HK2 on cell death and growth of U343 cells, which do not express HK2 endog enously. Previously characterized HK2 mutant constructs (Sun et al., 2008 ; M2, lacks the catalytic domains required to phosphorylate glucose, but can translocate to bind mitochon dria; T2, lacks the Nterminal mitochondrialbinding domain, but can phosphorylate glucose; TM2, lacks ability for glucose depletion of HK2. Interestingly, depletion of total PKM2 resulted in elevated total HK activity (Fig. 5 B) , suggesting com pensatory mechanisms engaged by cells to increase glucose flux, yet resulting in mod est but not significant increases in lactate levels and a small increase in PDHE1a ex pression (Fig. 5, A and C) . Lastly, we wished to determine whether depletion of HK2, HK1 or PKM2 glycolytic enzymes in GBM cells may have resulted in compensatory increase in the alternatively spliced PKM1, expressed in normal brain and associated with OXPHOS (Christofk et al., 2008) . To address this, we performed a PKM2 splice assay (David et al., 2010) and found that the percentage of PKM2 over total PKM1 AND PKM2 did not change significantly with loss of HK2 or HK1 (Fig. 5 G) . However, the overexpression of HK1 in cells with increased GLUT1 expression at the transcript level in cells depleted of HK2 and HK1 (Fig. 5 F) . Furthermore, HK2depleted cells showed significantly reduced LDHA transcript expression, correlating with the reduction in lactate (Fig. 5 F) .
Although glucose flux was not measured directly, the increase in PDHE1a expression coupled with enhanced O 2 consumption and decreased lactate levels suggest there is greater flux of glucose to oxidative metabolism with (F) Extracellular lactate in cells overexpressing HK2-GFP, HK1-GFP, or control (GFP only) was measured by NADH-coupled enzyme reaction with absorbance measured at 490 nm on day 3 and normalized to cell number. BrdU, caspase 3 and 7, and lactate measurements were performed in triplicates and graphs show mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01.
HK2 regulates growth and angiogenesis in orthotopic xenograft models of GBM
Stereotactic intracranial injections of U87 controls (U87 scr shRNA or U87empty vector, n = 10), U87HK2shRNA tagged with RFP (n = 10), U87 overexpressing HK2 GFP (n = 10) or a mixed U87 HK2shRNARFP+U87HK2 GFP group (n = 6) were undertaken. Mice injected with U87HK2shRNARFP survived significantly longer than those injected with either U87 controls, U87HK2GFP or mixed cells (P < 0.01; Fig. 6 A) . HK2 overexpressing mice or the mixed group did not live as long as the U87 controls (P < 0.01). Although there was no difference in survival and pathology between the U87HK2GFP and mixed group, only the U87HK2GFP cells were observed in mixed tumors, reflecting a growth advantage for cells overexpressing HK2 (Fig. 6, A, B, and D) .
The majority of tumors with decreased HK2 did not form large tumors (Fig. 6 B) . However, U87HK2shRNA RFP tumor cells invaded the perivascular VirchowRobin spaces and tracked along leptomeninges in both hemispheres, a phenomenon not seen in control tumors. Tumor cells that were depleted of HK2 could even be found deep within the depleted of HK2 resulted in the suppression of PKM2 to levels similar to PKM2shRNA cells.
Subcutaneous growth of HK2-deficient GBM cells is impaired
To determine the effect of stable loss of HK2 on in vivo subcutaneous xenografts, U87 scr shRNA (n = 7) or U87 HK2shRNA cells (1 and 2; n = 4 each) were injected subcutaneously into NODSCID mice. By 4 wk, the scr shRNA group had substantial tumors, whereas no visible tumor was seen in mice injected with U87HK2shRNA (Fig. S6 A) . At 8 wk, 3/8 U87HK2shRNAinjected mice remained tumor free (P < 0.001; Fig. S6 A) . The scr shRNA tumors showed large regions of necrosis (N) and HIF1 positivity with decreased apoptosis as measured by cleaved caspase 3 compared with U87HK2shRNA1 xenografts (1 vs. 4%; Fig. S6 B) . (G) PKM splicing assay was performed on cells from panel A. Splice assay consists of PCR of PKM, followed by digestion with the enzyme PstI, generating products corresponding to the M1 and M2 isoforms. The percentage of M2 over total PKM is depicted below. All experiments represent mean ± SEM of three independent experiments. *, P < 0.05; **, P < 0.01 cerebellum (Fig. 6 C) . The extent of invasion, as quantified by measuring the mean distance (micrometer) of invading tumor clusters away from the tumor mass, was increased in both U87HK2GFP and U87HK2shRNARFP tumors com pared with U87 controls (P < 0.01; Fig. 6 C) . However, inva sion by the overexpressing HK2 tumor cells was more local in the adjacent parenchyma.
The tumor vasculature (vWF positivity) was reduced in U87HK2shRNARFP, with RFPtagged tumor cells migrat ing along existing normal brain vessels (Fig. 6, D and E) . In comparison, U87HK2GFP tumors showed numerous ir regularly shaped and distorted vessels, especially at the leading edge (Fig. 6, D and E) , in contrast to the smaller vessels found throughout the U87 control tumors. The U87HK2GFP and U87 controls, in contrast to HK2 depleted tumors, showed sporadic expression of HIF1 and expression of vascular en dothelial growth factor (VEGF; Fig. 6 D) . U87HK2shRNA RFP tumors had a decreased proliferative index (MIB1, 34.2 ± 4.4%; Fig. 6 , E and F), whereas the U87HK2GFP tumors had a higher proliferative index (64.4 ± 8.8%), even com pared with U87 controls (47.5 ± 2.5%; Fig. 6 , E and F). Cleaved caspase 3 levels were elevated in tumors with re duced HK2 (12 ± 3%) compared with control (3 ± 1.3%) and HK2GFP (2 ± 1.5%; Fig. 6 E) . In summary, inhibition of HK2 restricted growth of human GBMs within the intracra nial environment, with decreased angiogenesis but enhanced perivascular invasion.
Because of decreased HIF1 seen in subcutaneous and intracranial tumors (Fig. 6 and Fig. S6 ), we wished to deter mine whether HK2 depletion decreases HIF1 levels by altering either its synthesis or its degradation by prolyl hy droxylases (PHD). qRTPCR of cells depleted of HK2 revealed no significant difference in synthesis of HIF1 tran script (Fig. S6 C) . Interestingly, PHD2 protein expression was found to be increased in cells depleted of HK2, suggesting there may be greater degradation of HIF1 protein (Fig. S6 D) . Further supporting the decrease in angiogenesis seen in vivo, cells depleted of HK2 showed reduced intracellular VEGF levels (Fig. S6 D) .
DISCUSSION
Proliferating cells use aerobic glycolysis to assist in their growth (Vander Heiden et al., 2009) . In several types of can cer, a shift to aerobic glycolysis occurs with active suppression of OXPHOS. This metabolic switch may be reversible and partly result from aberrant regulation of glycolytic enzymes (Bonnet et al., 2007; Gatenby and Gillies, 2004; Plas and Thompson, 2002) . Therefore, a better understanding of the drivers of the Warburg effect is of biological and therapeutic interest. Results of this study collectively show HK2 to be a major regulator of aerobic glycolysis in GBMs.
Consistent with published microarray data (Dong et al., 2005; Parsons et al., 2008) and The Cancer Genome Atlas dataset, we demonstrate aberrant expression of HK2 in a large percentage of GBMs (Fig. 1, A and B) , with minimal expres sion in normal brain or LGAs. GBMs that express HK2 have a poorer overall survival. Mining of the Repository of Mo lecular Brain Neoplasia Data (REMBRANDT), in which human glioma samples have been collected from patients en rolled in the Glioma Molecular Diagnostic Initiative study, corroborates our prognostic results that HK2 predicts poor overall survival in glioma patients (REMBRANDT, 2005) . In addition, there was regional variation within GBMs, with greater HK2 expression in the highly proliferating and apoptosisresistant perinecrotic central regions compared with the invading peripheral GBM cells (Fig. 1 C and Fig. S1 C) . This suggests that HK2 may provide a survival and prolifer ative advantage in vivo, especially within harsher tumor microenvironments. There does not appear to be a relationship between GBM samples expressing HK2 compared with mutant IDH1 based on our results and TCGA subtype analy sis (Verhaak et al., 2010) .
Our in vitro experiments demonstrated that transient in hibition of HK2 in GBM cells decreased proliferation and sensitized cells to therapeutic apoptotic stimuli such as radio therapy and the chemotherapeutic oral alkylating agent TMZ (Fig. 2, C and D; and Fig. S3, C and D) . Stable depletion of HK2 inhibited aerobic glycolysis and promoted normal oxi dative glucose metabolism, as exemplified by decreased extra cellular lactate, increased expression of OXPHOS proteins and increased O 2 consumption (Fig. 3) . In support of this, overexpression of HK2 promoted proliferation, resistance to apoptosis, and lactate formation (Fig. 4) . The addition of HK1 to cells lacking HK2 resulted in the rescue of total HK activ ity, but did not rescue the phenotype of aerobic glycolysis in GBM cells (Fig. 5, A-D) , supporting a unique role of HK2 over HK1 in GBM growth. Similarly, depletion of the down stream ratelimiting enzyme PKM2 did not significantly alter lactate levels or oxygen consumption in GBM cells. However, this study did not examine the impact on metabolism of the rescue of GBM cells depleted of PKM2 with expression of adult PKM1 splice isoform, previously shown to impact aero bic glycolysis (Christofk et al., 2008) .
The exact mechanisms of how HK2 inhibits OXPHOS and promotes proliferation and lactate formation remain un clear; however, both glucose phosphorylation and mitochon drial localization contributed to these effects, as demonstrated by expression of HK2 mutants in GBM cells (Fig. 4) . HK2 has been previously shown to interact with VDAC at the mito chondria and regulate the release of cytochrome c and apop tosis, although the mechanistic details regarding opening or closure of permeability transition pore (and associated de polarization or hyperpolarization of mitochondria) and the release of cytochrome c are not well understood (Pastorino et al., 2002; Majewski et al., 2004) . Notably, HK2 transloca tion is regulated by growth factor-induced oncogenic signaling pathways, such as increased EGFR and PI3K-AKT activation, known to be aberrant in GBMs (Mellinghoff et al., 2005) . Mitochondrial binding of HK2 also alters its expression and function by reducing feedback inhibition from its end prod uct, glucose6phosphate, to increase its stability (Fig. S5 D) and promote glycolytic flux and overall ATP levels by using VEGF, HIF1 , and HK2 inhibitors are warranted to see if there is a synergistic effect and more importantly, if com bining these treatments can negate the invasive escape pheno type when these inhibitors are used as mono therapies.
In summary, inhibition of HK2 in GBMs results in resto ration of normal oxidative glucose metabolism in association with decreased HIF1 and VEGF expression, resulting in im paired tumorigenic growth and reduced angiogenesis. The mechanisms underlying the enhanced invasiveness with de pletion of HK2 are subject to further investigations, including the determination of whether this effect is HIF1 and/or VEGF dependent. This altered metabolism was not observed with loss of HK1, and is suggestive of aberrant HK2 expres sion being an important regulator of aerobic glycolysis in GBMs, but does not rule out the possibility of its working in conjunction with other specific downstream glycolytic en zyme isoforms. Exploiting tumor cells dependence on the Warburg effect by altering or reprogramming cell metabolism provides an attractive therapeutic approach. Because HK2 ex pression is limited in the normal adult brain, with HK1 being the predominant isoform, targeting HK2 or its function may be a way of selectively killing GBM cells while limiting toxic ity to surrounding normal tissue. Current agents targeting HK2 (e.g., 3bromopyruvate, 2deoxyglucose) may have lim ited clinical potential caused by nonspecificity (e.g., target HK1 or other metabolic proteins as well) and systemic toxic ity. To circumvent this, specific inhibitors of HK2 or of its mitochondrial translocation that can be administered using local delivery strategies already used in GBM clinical trials (Ferguson and Lesniak, 2007) should be developed. The intra cranial xenograft data suggests that although overall growth and survival is improved by genetic inhibition of HK2 and rectification of normal glucose metabolism, increased inva sion may be a longterm consequence, which may impact the therapeutic suitability of targeting the Warburg effect singu larly. However, selectively targeting of the Warburg effect in GBM with current modalities of treatment may provide syn ergism and enhance overall treatment efficacy. Whether the increased sensitivity to radiation and chemotherapy conferred by reduction of HK2, as in in vitro results, offsets this longer term increased invasion, will require further interrogation.
MATERIALS AND METHODS
Human GBM samples. Stereotactically guided GBM samples were ac quired. These were verified by C. Hawkins, coauthor and neuropatholo gist, for the presence of perinecrotic pseudopalisading tumor cells (center) and infiltrating tumor cells (periphery). Approval from the University Health Network Research Ethics Board was obtained for research on human samples.
qRT-PCR. Total RNA was extracted from frozen tissue samples or GBM cells using the RNEasy kit (QIAGEN), and cDNA was synthesized using the QuantiTect RT kit (QIAGEN). qRTPCR was performed using SYGR green (Invitrogen) and the Chromo4 Real Time PCR detector (BioRad Laboratories). The following primers were used: HK1, 5GGACTGGACC GTCTGAATGT3 and 5ACAGTTCCTTCACCGTCTGG3; HK2, 5CAAAGTGACAGTGGGTGTGG3 and 5GCCAGGTCCTTCA CTGTCTC3; HPRT1, 5TGACACTGGCAAAACAATGCA3 and preferentially using mitochondrial ATP (Bustamante and Pedersen, 1977) . In contrast to HK2, HK1 mitochondrial lo calization was not regulated by growth factor signaling path ways in GBMs (Fig. 4 and Fig. S5 ). Our data supports that HK2 suppresses both apoptosis and oxidative metabolism, al though the temporal order of events and mechanisms linking mitochondrial membrane depolarization, enhanced OXPHOS, release of cytochrome c, and decreased proliferation with loss of HK2 require further investigation. Putative mechanisms may include interaction between altered mitochondrial mem brane permeability, generation of reactive oxygen species, and activation of cell cycle inhibitors such as TP53 or P21 CIP1 , among other events. One possible effector mechanism through which depletion of HK2 can promote a return to OXPHOS is by increased expression of the transcription factors PGC1 and mTFA, which are important for the expression of metabolicassociated genes such as OXPHOS genes (Fig. 3 D) . PGC1 has previously been shown to act as a dominant reg ulator of mitochondrial function, respiration, and biogenesis (Rohas et al., 2007) .
Reduction of HK2 expression in GBM cells also had in vivo antitumorigenic effects in both subcutaneous and intra cranial xenograft models (Fig. 6 A and Fig. S6 A) . Mixing experiments with HK2depleted and HK2overexpressing GBM cells clearly demonstrated a proliferative advantage of the latter (Fig. 6, A and D) . Both subcutaneous and intracra nial HK2depleted GBM xenografts grew slowly and had in creased apoptosis (Fig. 6 E and Fig. S6 B) . However, they differed in one potentially important aspect; the small intra cranial GBM tumors with HK2 knockdown were much more invasive and tracked along perivascular spaces deep in both hemispheres (Fig. 6, B-D) . This difference may reflect the poorly vascularized subcutaneous environment compared with the highly vascular intracranial microenvironment. The increased invasive nature intracranially is reminiscent of the longerterm effects of VEGF inhibition and antiangiogenic therapies on GBM growth in intracranial models and human clinical trials (Blouw et al., 2003; PaezRibes et al., 2009) . A possible molecular explanation of the increased invasion by GBMs with HK2 knockdown may relate to HIF1, which was decreased relative to control tumors or tumors over expressing HK2. Reduction of HIF1 would inhibit its transcriptional targets such as VEGF and provide a plausible explanation of the phenotypic similarity between HK2 knockdown, VEGF, or HIF1 knockdown in in vivo GBM models (Blouw et al., 2003; PaezRibes et al., 2009) . In sup port of this, it has been reported that GBMs with HIF1 knockdown grow poorly subcutaneously, but grow highly in vasive tumors intracranially (Blouw et al., 2003) . The decrease in HIF1 that we see in vivo in our tumors lacking HK2 may be caused by the fact that these tumors never grow beyond a size prompting HIF1 stabilization from microenvironmental influences. Alternatively, we show that HK2depleted GBM cells express less VEGF and HIF1 in vitro, the latter linked with greater expression of PHD2, potentially hastening its degradation. In vitro and in vivo combinatorial treatments Mitochondrial membrane permeability and immunofluorescence. Mitochondrial membrane potential was assessed with JC1 dye (Invitrogen). Cells were grown on coverslips, incubated under normoxic or hypoxic con ditions for 24 h, and loaded for 20 min with 2 µM of JC1 in HBSS at 37°C. Cells were then washed in PBS, maintained at 37°C, and excited with 540 and 488 nm lasers to visualize the aggregate and monomer signals, respec tively. The mean ratios of red versus green fluorescent signal intensities (relative pixel intensity) were measured for 10 U87 HK2shRNA1 and 10 U87 scram ble shRNA cells in 3 independent experiments. Immunofluorescence of live cells stained with 50 nM of MitoTracker Deep Red (Invitrogen) for 20 min was also performed. Images were taken on an Axiovert 200 (Carl Zeiss, Inc.) equipped with a Hamamatsu Orca AG CCD camera and spinning disk con focal scan head using Volocity acquisition software. Regions of interest were drawn on the image data and the software. We then summed the chosen pix els to generate a fluorescence ratio or percentage of colocalization. Signal within the nucleus was used as background fluorescence.
Western blot analysis. Cell lines were lysed in modified PLC lysis buffer and protein concentration determined using the BCA assay (Thermo Fisher Scientific). Membranes were probed overnight with the following antibodies: actin Mitochondrial fractionation and cytochrome c ELISA. 10 million U87 scramble shRNA, U87 HK2shRNA1, and U87HK2shRNA2 were harvested and fractionated into cytosolic and mitochondrial fractions using a mitochondrial fractionation kit (Thermo Fisher Scientific). ELISA for cyto chrome c was performed on the cytosolic fraction according to the manufac turer's protocol (R&D Systems) and was normalized to total protein content.
Oxygen consumption and lactate and glucose uptake assays. Lactate assay was performed according to manufacturer's protocol and normalized to cell number (Eton Bioscience). For glucose uptake, 1 million cells were stained with fluorescent dglucose analogue 2[N(7nitrobenz2oxa1,3 diazol4yl) amino]2deoxydglucose (2NBDG; 100 µM; Invitrogen) for 30 min, washed with PBS, and analyzed by flow cytometry. O 2 consumption was measured using a model 110 Fiber optic oxygen monitor (Instech). Cells were trypsinized and counted, and 5 million cells were resuspended in 500 µl of media, warmed at 37°C. Measurements were made in triplicates in three independent experiments and reported as nmol O 2 /million cells/min. HK assay. HK activity was measured as previously described (Ahmad et al., 2002) . Cells were lysed using the following buffer: 50 mM potassium phos phate, 2 mM dithiothreitol (DTT), 2 mM EDTA, and 20 mM sodium fluo ride. 1 ml of buffer was used to harvest 5 million cells. After the cells were harvested, the cell homogenate was incubated on ice for 30 min, followed by centrifugation at 1,000 g at 4°C for 10 min. Approximately 10 µl of freshly lysed cell supernatant was added to 1,000 µl of 100 mM TrisHCl, pH 8.0, 0.5 mM EDTA, 10 mM ATP, 10 mM MgCl 2 , 2 mM glucose, 0.1 mM NADP, and 0.1 U/ml of G6PD (SigmaAldrich). HK activity was determined by following the G6Pdependent conversion of NADP to NADPH spectro photometrically at 340 nm at 37°C. One activity unit is defined as micro moles of NADPH per milliliter per minute at 37°C. Subcutaneous GBM xenograft model. Animal studies were performed with the approval of the Hospital for Sick Children. NODSCID mice were injected subcutaneously with 1.5 × 10 6 U87 scr shRNA (n = 7) or U87HK2shRNA1 and 2 cells (n = 4 each). Mice were observed for tumor formation, and then sacrificed. Tumors were harvested at 4 wk (U87 scr shRNA) or 8 wk (U87HK2shRNA1, 2). 5GGTCCTTTTCACCAGCAAGCT3; PGC1, 5TCAGTCCTCAC TGGTGGACA3 and 5TGCTTCGTCGTCAAAAACAC3; mTFA, 5AATGGATAGGCACAGGAAACC3 and 5CAAGTATTATGCTG GCAGAAGTC3; HIF1, 5CGTTCCTTCGATCAGTTGTC3 and 5TCAGTGGTGGCAGTGGTAGT3.
Immunohistochemistry. Immunohistochemical staining was performed on formalinfixed, paraffinembedded 5µm thick GBM tissue. Citrate antigen retrieval was performed. Overnight incubation at 4°C with primary anti body was performed (Table S2) . Detection was performed using VectaStain ABC reagent and DAB chromogen (Vector Laboratories). TUNEL immuno histochemistry was performed with the DeadEnd colorimetric TUNEL System (Promega). The apoptotic index (percentage) was calculated as the number of positive nuclei over total nuclei. GBM tissue microarray with prognostic information was acquired from P. Mischel (University of Califor nia, Los Angeles, Los Angeles, CA) and stained with HK2. An interrater reliability analysis using Cohen's  statistic was performed to determine con sistency among ratings. Mutant IDH1 antibody was generously provided by A. von Deimling (University of Heidelberg, Heidelberg, Germany).
Cell lines. The U87 (p53 wt) and U373 (p53mut; obtained from D. Bigner, Duke University, Durham, NC) and U343 GBM lines were maintained in DME, 10% FBS, and antibiotics. Hypoxic conditions were achieved by incu bating cells in a tissue culture incubator flushed with N2, 5% CO 2 , and O 2 levels maintained constant at 2% using an oxygen controller (ProOx; Bio spherix Ltd). Cells were transfected with either 50 nM of HK2 siRNA or 50 nM of scramble siRNA, or mocktransfected using HiPerFect transfection reagent (QIAGEN). In overexpression studies, cells were transfected with HK1GFP and HK2 constructs provided by H. Ardehali (Northwestern University, Evanston, IL) using FuGENE transfection reagent (Roche). Cells were treated with AG1478 (EMD) for 24 h at 2 µM or AKT inhibitor VIII (EMD) for 6 h at 2 µM.
Cell viability assay and BrdU incorporation assay. Cell viability was measured using the SRB colorimetric assay (SigmaAldrich) and trypan blue exclusion. Proliferation was measured by BrdU incorporation assay (Pro mega) according to the manufacturer's protocol. For BrdU, cells were nor malized to a standard curve of known concentration of cells.
Determination of apoptosis.
Cells were seeded into a 96well plate, trans fected with siRNA, and at 3 d after transfection administered 5 Gy radiation or 24 h of 2% hypoxia. Caspase 3 and 7 activity levels were measured using the ApoOne Homogeneous caspase 3 and 7 assay (Promega). This assay in cludes a profluorescent caspase 3 and 7 consensus substrate and rhodamine 110 containing a DEVD peptide substrate sequence that, upon cleavage, be comes fluorescent when excited at a wavelength of 498 nm. The emission maximum is 521 nm. The amount of fluorescent product generated is repre sentative of the amount of active caspase 3 and 7 present in the sample. Apoptosis was also assessed with fluorescenceactivated cell sorting analysis (FACScan; BD) of live cells stained with Annexin VFITC/PI (BD).
Generation of stable cell lines. Target sequences from HK2 siRNA 1 and 2 were used to design shRNA. shRNA for HK2, HK1, PKM2, and scramble shRNA were annealed and then cloned into RNAi Ready pSIRENretroQ vector (Takara Bio Inc.). The following siRNA target sequences were used: HK2, siRNA1 5CACGATGAAATTGAACCTGGT3; HK2, siRNA2 5CCTGGGTGAGATTGTCCGTAA3. The HK1 shRNA sequence used was 5CACGATGTAGTCACCTTACTA3. The PKM2 shRNA target sequence used was 5GCTGTGGCTCTAGACACTAAA3. U87HK2shRNA cells were also stably transfected with HK1GFP and U87 cells with HK2GFP, both provided by H. Ardehali. For PKM splicing assay, PCR of PKM was performed, followed by digestion with PstI (PKM exon 8 forward, 5CTGAAGGCAGTGATGTGGCC3; PKM exon 11 reverse, 5ACCCGGAGGTCCACGTCCTC3). Products were resolved on 2% agarose gel.
Intracranial GBM model. NODSCID mice were stereotactically injected with 200,000 cells of U87 control (U87 + empty vector and U87 scramble shRNA, n = 10), U87HK2shRNA + RFP, U87HK2GFP (n = 10), or U87HK2GFP + HK2shRNARFP (n = 6). Upon development of symp toms, mice were anesthetized and perfused with 4% PFA, and brains har vested followed by flash freezing or paraffin embedding.
Statistical analyses. qRTPCR and in vitro experiments were performed in triplicates. Means and standard errors were computed. Student's t test or Wilcoxon sign rank t test was performed to determine whether a significant difference exists between groups. Analysis of patient survival was performed using KaplanMeier plots generated in SPSS, using age as a covariate, and sta tistical significance was measured using the Cox proportional hazard.
Online supplemental material. Fig. S1 shows staining of HK2, mutant IDH1, and TUNEL in GBM samples. Fig. S2 shows that inhibition of HK2 results in decreased cell viability in GBM cells, including under hypoxia. Fig. S3 shows that inhibition of HK2 in GBM explants reduces proliferation and sensitizes to radia tion and TMZ. Fig. S4 shows no significant impact on mitochondrial structure and count in U87 cells depleted of HK2, HK1, or PKM2. Fig. S5 shows that growth factor-PI3KAKT signaling is important for localization of HK2, but not HK1, to outer mitochondrial membrane, and is necessary for the growth promoting effects of HK2. Fig. S6 shows that stable loss of HK2 decreases in vivo GBM growth in a subcutaneous xenograft model, in addition to decreased HIF1 stability and VEGF expression with inhibition of HK2. Table S1 shows the pairwise comparison in expression of HK2 transcript across GBM subtypes using Significance Analysis of Microarrays (Verhaak et al., 2010) . Table S2 lists the pri mary antibodies used for immunohistochemical staining with dilutions. shRNA and primer sequences are available upon request. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20101470/DC1.
